Two weeks after a neuromodulator treatment, the patient sits in front of the injector and points to a persistent line above the lateral brow. The frontalis is mostly relaxed, but one corrugator is still active. Is this a touch-up — a minor dose adjustment to an otherwise successful treatment? Or is this a complication — a sign of uneven diffusion, inappropriate placement, or an anatomical variant the initial assessment missed?
The distinction matters because the documentation, clinical response, and patient communication are completely different. A touch-up is a planned, routine adjustment within the standard treatment window. A complication is an adverse event that requires clinical evaluation, incident documentation, and potentially a different intervention. Practices that conflate the two expose themselves to documentation gaps, patient dissatisfaction, and liability.
This article is for med spa owners, medical directors, and injectors who need a structured touch-up policy — one that defines when a touch-up is appropriate, how to document it, how to communicate it to the patient, and where the line is between a touch-up and a complication that requires escalation.
The 2-Week Follow-Up Window
Neuromodulators (onabotulinumtoxinA, abobotulinumtoxinA, incobotulinumtoxinA, prabotulinumtoxinA, daxibotulinumtoxinA) reach peak clinical effect at approximately 10–14 days post-injection. This timeline is consistent across the product family, though onset may be perceived slightly faster with some formulations. Consensus recommendations published in peer-reviewed literature support offering a follow-up appointment at two weeks for patients receiving botulinum toxin type A either for the first time or in a new treatment area.
The two-week window is the clinically appropriate time to assess results and perform any dose adjustment. Before two weeks, the product has not reached full effect, and any "adjustment" is premature. After two weeks, the patient is approaching the treatment's steady state, and the opportunity to document the result in the context of the initial treatment plan diminishes.
Why the first-treatment follow-up matters
For patients new to neuromodulators or new to a specific treatment area, the two-week follow-up serves three purposes:
- Assess individual response. Muscle mass, injection depth, anatomical variation, and product diffusion patterns differ between patients. The first treatment is as much a diagnostic procedure as a therapeutic one.
- Establish a dose baseline. The follow-up allows the injector to determine whether the initial dose was appropriate, insufficient, or excessive — and to adjust the treatment plan for future visits.
- Build trust and set expectations. Patients who are offered a follow-up and see that the practice stands behind its work are more likely to return for maintenance treatments and refer others.
Defining a Touch-Up vs. a Complication
What constitutes a touch-up
A touch-up is a minor dose adjustment performed during the two-week follow-up window to address residual muscle activity in a previously treated area. Characteristics:
- The treatment was otherwise successful — most of the targeted muscles are appropriately relaxed.
- A small area shows incomplete response, typically due to individual muscle mass variation, injection depth variation, or diffusion pattern.
- The adjustment requires a small number of additional units (typically 2–8 units of onabotulinumtoxinA equivalent).
- No adverse events are present — no ptosis, no diplopia, no asymmetrical brow position, no ectropion.
What constitutes a complication requiring escalation
Any of the following should be documented as a potential complication and evaluated by the supervising physician or a senior injector, not managed as a routine touch-up:
- Brow ptosis. The eyebrow has dropped below its natural position, suggesting excessive diffusion into the frontalis or inappropriate injection placement too close to the brow.
- Eyelid ptosis. The upper eyelid droops, suggesting diffusion into the levator palpebrae superioris. This is a documented adverse event in the Botox (onabotulinumtoxinA) prescribing information and requires specific management (apraclonidine drops, patient counseling on expected duration).
- Diplopia or blurred vision. Any visual disturbance after neuromodulator injection requires immediate clinical evaluation.
- Significant asymmetry. Marked difference between sides that was not present before treatment, beyond what a minor touch-up can address.
- "Quizzical" or cocked eyebrow. Uneven frontalis relaxation causing a peaked brow appearance. Although often manageable with touch-up injections, its frequency warrants specific documentation.
- Patient-reported functional impairment. Difficulty raising the eyebrows, closing the eyes, eating, speaking, or any functional limitation.
The practice's touch-up policy should include a clear decision tree: if the follow-up reveals any of these findings, the injector does not proceed with a touch-up. Instead, the case is documented as a potential adverse event, the supervising physician is notified, and a treatment plan specific to the complication is developed.
Documentation Standards for Touch-Ups
Every touch-up must be documented in the patient's treatment record with the same rigor as the initial treatment. The following elements should be recorded:
Initial treatment record (day 0)
- Product name, lot number, expiration date
- Reconstitution details (diluent volume, concentration)
- Number of units injected per site, with a facial map or anatomic diagram
- Injection technique (needle vs. cannula, depth, injection points)
- Patient's pre-treatment photographs (standardized positioning and lighting)
- Informed consent documentation
- Pre-treatment assessment of muscle activity and asymmetries noted before injection
Follow-up and touch-up record (day 10–14)
- Comparison photographs at the same standardized positioning and lighting
- Assessment of each treated area: satisfactory response, incomplete response, or adverse finding
- Specific notation of any residual muscle activity — which muscle, which side, graded severity
- If touch-up is performed:
- Additional units injected per site, with facial map
- Product lot number (same or different vial)
- Rationale for the adjustment (e.g., "residual corrugator activity left side, 4 units added")
- If complication is identified:
- Detailed description of the finding
- Notification of supervising physician (documented with date and time)
- Treatment plan for the complication
- Patient communication and counseling documented verbatim or in summary
- Follow-up plan (timing of next assessment)
Why lot numbers matter for touch-ups
If a touch-up uses product from a different lot number than the initial treatment, and the patient later reports an adverse event, the practice needs to be able to trace which lot was used in which site. This is not just a best practice — it is a regulatory expectation for any practice subject to medical board oversight or FDA adverse event reporting requirements.
Touch-Up Pricing Policies
Practices handle touch-up pricing in three ways:
Complimentary within the follow-up window
The most common approach. Touch-ups performed at the two-week follow-up are included in the original treatment price, up to a defined unit ceiling (e.g., 10 units). This positions the practice as standing behind its work and encourages patients to return for the follow-up. The cost of the additional product is minimal relative to the patient-retention benefit.
Charged at product cost only
The patient pays only the per-unit cost of the additional product used, without the treatment fee. This is a middle ground that covers the practice's hard cost without charging the patient a second treatment fee for an incomplete initial result.
Charged as a new treatment
Full price for additional units. This is uncommon for touch-ups at the two-week follow-up and generally creates patient dissatisfaction, as the patient perceives they are being charged for an incomplete initial treatment.
The critical caveat: documenting the charge decision
Whichever policy the practice adopts, it should be documented in the practice's standard operating procedures and applied consistently. If touch-ups are complimentary, the policy should specify:
- The time window (e.g., within 14–21 days of initial treatment)
- The maximum additional units covered
- Whether the policy applies to all patients or only to patients who attend the scheduled follow-up
- Whether the policy applies per treatment area or per visit
Inconsistent application of touch-up pricing is a common source of patient complaints and, in some cases, board complaints.
Patient Communication: Scripts That Protect the Practice
How a practice communicates about touch-ups and follow-ups matters as much as the clinical management. The following framework positions the conversation correctly:
At the initial treatment (day 0)
"Neuromodulators take 10–14 days to reach full effect. We'd like to see you back at the two-week mark to assess your results. At that visit, if any area needs a small adjustment, we'll take care of it. This follow-up is included in your treatment."
This sets the expectation that a follow-up is standard — not optional — and that minor adjustments are normal, not a sign of error.
At the follow-up (day 10–14), if a touch-up is appropriate
"Most of the treatment looks great — the [frontalis/corrugators/crow's feet] are well-relaxed. I see a small area of residual activity here [point to area]. This is common and reflects how your specific muscles respond. I'd like to add a few units to this area to complete the result."
This normalizes the adjustment, attributes it to individual anatomy rather than technique, and keeps the patient confident in the practice.
At the follow-up, if a complication is identified
"I want to discuss something I've noticed in your result. [Describe the finding clearly and factually.] This is a recognized, temporary effect of neuromodulator treatment. It typically resolves within [timeframe]. I'd like to [outline the management plan]. I'm also going to have [supervising physician/senior provider] review your case to make sure we're managing this optimally. Let me tell you what to expect and when to contact us."
This is transparent, non-defensive, and focuses on the management plan. It avoids blame, avoids minimizing the finding, and documents that the practice took the complication seriously.
What not to say
- "This sometimes happens when patients move around too much after treatment." (Blames the patient, unsupported by evidence.)
- "It's normal, don't worry about it." (Dismissive, does not document the finding, and is clinically inaccurate if the finding is a complication.)
- "You just need more Botox." (Suggests the initial treatment was intentionally underdosed to generate a follow-up charge — a perception that damages trust.)
The Underdosing Question
Some practices intentionally underdose neuromodulators at the initial treatment with the plan to "touch up" at two weeks. This approach is sometimes called "start low, go slow" and has legitimate clinical rationale for patients who are treatment-naive, have thin muscle mass, or are at risk for an undesirable frozen appearance.
However, underdosing as a business strategy — deliberately using fewer units than clinically appropriate to create a two-visit treatment cycle and charge for both — is:
- Clinically indefensible. Consensus guidelines recommend using the smallest dose that achieves the desired result, not a dose that is predictably insufficient.
- Regulatory risk. Medical boards view pattern underdosing followed by paid touch-ups as a billing integrity issue.
- Patient retention negative. Patients who feel they are being under-treated to generate a second visit will not return long-term.
A practice that chooses a conservative initial dose should do so for documented clinical reasons and should include the anticipated follow-up dose in the original treatment plan — not bill it as a separate event.
Building the Practice Policy
A complete touch-up policy should be a written document, approved by the medical director, and accessible to all clinical staff. It should cover:
- Definition. What constitutes a touch-up versus a complication, with examples.
- Timing. The follow-up window (10–14 days is standard) and when the practice will offer the follow-up appointment.
- Documentation. Required chart elements for the initial treatment, follow-up assessment, and any touch-up or complication management.
- Pricing. Whether touch-ups are complimentary, cost-only, or charged — with unit ceilings and time windows clearly stated.
- Escalation. When the injector must notify the supervising physician and what constitutes a reportable adverse event.
- Communication. Approved scripts for patient conversations at the initial treatment, follow-up, touch-up, and complication scenarios.
- Audit. How often the medical director reviews touch-up records (monthly is a common minimum) and what metrics are tracked (touch-up rate by injector, complication rate, patient satisfaction).
A high touch-up rate for a single injector may indicate underdosing, inconsistent technique, or inadequate initial assessment — and should trigger a competency review, not just a chart note. A low touch-up rate may indicate appropriate initial dosing — or may indicate that patients are not returning for follow-up, which is a separate problem.
Sources
- Carruthers J, Fagien S, Matarasso SL, and the Botox Consensus Group, consensus recommendations on botulinum toxin type A treatment parameters (published in Dermatologic Surgery)
- PMC, "Facial aesthetic injections in clinical practice: Pretreatment and posttreatment consensus recommendations to minimise adverse outcomes": https://pmc.ncbi.nlm.nih.gov/articles/PMC7497045
- PMC, "Are Post-Care Recommendations Following Upper-Face Botulinum Toxin Treatment Scientifically Necessary? A Retrospective Study Based on 5000 Patients": https://pmc.ncbi.nlm.nih.gov/articles/PMC12390119
- ASDS, "Consensus Statement Regarding Storage and Reuse of Previously Reconstituted Neuromodulators": https://www.asds.net/Portals/0/PDF/asdsa/white-paper-storage-and-reuse-of-reconstituted-neuromodulators.pdf
- American Med Spa Association (AmSpa), "How Safe Med Spas Manage Complications": https://www.americanmedspa.org/news/how-safe-med-spas-manage-complications
- NorCal Group (now part of ProAssurance), "Supervision of Non-Physicians Performing Cosmetic Procedures": https://www.norcal-group.com/library/supervision-of-non-physicians-performing-cosmetic-procedures
- InjectAbility Institute, "Medical Spa Standard Operating Procedures, Protocols and Consents Package": https://www.injectabilityinstitute.com/cources/medical-spa-standard-operating-procedures-protocols-and-consents-package
- FDA, Botox (onabotulinumtoxinA) prescribing information: https://www.accessdata.fda.gov/scripts/cder/daf/
